SCHEMBL4437993

SCHEMBL4437993

O=C(O)c1ccc(Cl)cc1Sc1ccc(F)cc1C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.46
CASP1 P29466 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GRIK1 P39086 3/20 0.45
KEAP1 Q14145 1/20 0.44
HPGD P15428 3/20 0.43
HTT P42858 2/20 0.43
ALDH1A1 P00352 5/20 0.42
TP53 P04637 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
DHODH Q02127 1/20 0.41
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
PLA2G1B P04054 1/20 0.40
HSP90AA1 P07900 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4441135 0.92 ALDH1A1 (0.50) TSHRCASP1SMN1; SMN2GRIK1KEAP1
SCHEMBL8531547 0.90 HPGD (0.56) TSHRCASP1SMN1; SMN2GRIK1KEAP1
SCHEMBL4438684 0.89 KEAP1 (0.50) KEAP1HPGDALDH1A1CA1CA2
SCHEMBL8530044 0.88 ALDH1A1 (0.51) TSHRCASP1SMN1; SMN2GRIK1KEAP1
SCHEMBL4437772 0.85 KEAP1 (0.57) TSHRKEAP1HPGDALDH1A1CA1
SCHEMBL11573648 0.83 RHEB (0.56) TSHRCASP1SMN1; SMN2GRIK1ALDH1A1
SCHEMBL4440514 0.82 AGBL2 (0.52) TSHRCASP1SMN1; SMN2GRIK1KEAP1
SCHEMBL4444708 0.82 KEAP1 (0.44) KEAP1HPGDALDH1A1TP53DHODH
SCHEMBL4437995 0.82 ALDH1A1 (0.61) TSHRCASP1SMN1; SMN2GRIK1HPGD
SCHEMBL4440699 0.81 KDM4E (0.57) SMN1; SMN2KEAP1HTTALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061754-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2009-05-27 EP disclosed
WO-2008115999-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 WO disclosed
US-20080234384-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234384-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS FECH, SLC10A1, SLC40A1 TSHR 611/4885CASP1 2894/4885SMN1; SMN2 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.